clinical trial · NCT07532603
A Phase 2/3 Study of Brepocitinib in Adults With Lichen Planopilaris
Priovant Therapeutics, Inc.·phase3·recruiting·n = 342
Lichen PlanopilarisOral BrepocitinibPlacebo
brief summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris
started
Mar 19, 2026
primary completion
Dec 31, 2028
completion
Jul 31, 2029
last updated
Apr 16, 2026
official title
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Lichen Planopilaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol